Multidrug Resistance among Clinical Isolates of Pseudomonas aeruginosa………A Public Health problem Worldwide

Shamweel Ahmad

Abstract


Pseudomonas aeruginosa (P. aeruginosa) is an important cause of hospital acquired infections and the second most common pathogen isolated in intensive care unit infections. Surveillance of P. aeruginosa has exposed rising trends in multidrug-resistance. Multidrug-resistant forms of P. aeruginosa are associated with higher mortality and morbidity compared to other bacterial pathogens. Resistant P. aeruginosa is a public health problem that affects many countries of the world. Multidrug resistant P. aeruginosa harbours integrons and other mobile genetic elements such as plasmids and transposons, which easily disseminate antibiotic resistance genes among clinical strains of P. aeruginosa.


Full Text:

PDF

References


Ali A, Solh E, Alhajhusain A: Update on the treatment

of Pseudomonas aeruginosa pneumonia. J Antimicrob

Chemother 2009, 64:229–238.

Bonomo RA, Szabo D: Mechanisms of multidrug

resistance in Acinetobacter species and Pseudomonas

aeruginosa. Clin Infect Dis 2006,43:49–56.

Fonseca EL, Vieira VV, Cipriano R, Vicente AC: Class

integrons in Pseudomonas aeruginosa isolates

from clinical settings in Amazon region, Brazil. FEMS

Immunol Med Microbiol 2005, 44:303–309.

Yan JJ, Hsueh PR, Lu JJ, Chang FY, Ko WC, Wu JJ:

Characterization of acquired beta-lactamases and their

genetic support in multidrugresistant Pseudomonas

aeruginosa isolates in Taiwan: the prevalence of

unusual integrons. J Antimicrob Chemother 2006,

:530–536.

Chen J, Su Z, Liu Y, Wang S, Dai X, Li Y, Peng S, Shao

Q, Zhang H, Wen P, Yu J, Huang X, Xu H: Identification

and characterization of class 1integrons among

Pseudomonas aeruginosa isolates from patients in

Zhenjiang, China. Int J Infect Dis 2009, 13:717–721.

Ruiz-Martínez L, López-Jiménez L, Fusté E, Vinuesa T,

Martínez JP, Viñas M: Class 1 integrons in environmental

and clinical isolates of Pseudomonas aeruginosa. Int J

Antimicrob Agents 2011, 38:398–402.

Carattoli A: Importance of integrons in the diffusion

of resistance. Vet Res 2001, 32:243–259.

Elbourne LD, Hall M: Gene cassette encoding a 3-N

–aminoglycoside acetyltransferase in a chromosomal

integron. Antimicrob Agents Chemother 2006,

:2270–2271.

Jeong JH, Shin KS, Lee JW, Park EJ, Son SY: Analysis

of a novel class 1 integron containing metallo-betalactamase

gene VIM-2 in Pseudomonas aeruginosa.

J Microbiol 2009, 47:753–759.

Blondel-Hill, E., Henry, D., & Speert, D. (2007).

Pseudomonas. In P. Murray (Ed.), Manual of Clinical

Microbiology (9th ed., Vol. 1, pp. 734-747). Washington,

DC: American Society for Microbiology.

National Nosocomial Infections Surveillance System.

National Nosocomial Infections Surveillance (NNIS)

system report data summary from January 1992

through June 2004, issued October 2004. Am J of

Infect Cont 2004, 32, 470-485.

Rossolini, G., & Mantengoli, E. Antimicrobial resistance

in Europe and its potential impact on empirical therapy.

Cl Microbiol and Infect Dis, 2008, 14(Suppl 6), 2-8.

Sader H., Jones R., Gales C., Silva J., Pignatari A.,

SENTRY Participants Group (Latin America) SENTRY

antimicrobial surveillance program report: Latin

American and Brazilian results for 1997 through 2001.

Braz J of Infect Dis 2004, 8(1):25- 79.

McGowan J. Resistance in non-fermenting Gramnegative

bacteria: Multidrug resistance to the

maximum. The Am J of Med 2006, 119 (6A) S29-S36.

Siegel, J., Rhinehart, E., Jackson, M., Chiarello, J., &

The Healthcare Infection Control Practices Advisory

Committee. (2006). Management of Multidrug-resistant

organisms in healthcare settings, 2006. Atlanta, GA:

Center for Disease Control and Prevention: Retrieved

on February 15, 2010, from www.cdc.gov/ncidod/

dhqp/pdf/ar/mdroGuideline2006.pdf

Driscoll, J., Brody, S., & Kollef, M. The epidemiology,

pathogenesis and treatment of pseudomonas

aeruginosa infections. Drugs 2007, 67(3), 351-368.

Ruxana T., Sadikot S., Blackwell W., Prince C., & Prince

A., (2005) Pathogen–host interactions in Pseudomonas

aeruginosa pneumonia. American Journal of Respiratory

and Critical Care Medicine. 171.

Dwivedi A., Mishra R., Singh A., Azim A., Baronia N.,

Prasad K., (2009) Nosocomial cross- transmission

of Pseudomonas aeruginosa between patients in a

tertiary intensive care unit. Indian Journal of Pathology

and Microbiology. 52(4).

Yetkin G., Otlu B., Cicek A., Kuzucu C., and DurmazR., (2006) Clinical, microbiologic, and epidemiologic

characteristics of Pseudomonas aeruginosa infections

in a university hospital, Malatya, Turkey. Am J Infect

Control 34:188-92.

Safdar N., Handelsman J., Maki D., (2004). Effectiveness

of combination antimicrobial therapy for pseudomonas

aeruginosa bacteremia. Antimicrobial Agents

Chemotherapy, 47(9).

Streit , J., Jones, R., Sader, H., & Fritshe, T. (2004).

Assessment of pathogen occurrences and resistance

profiles among infected patients in the intensive care

unit: Report from the SENTRY antimicrobial surveillance

program (North America, 2001). International Journal

of Antimicrobial Agents, 24, 111-118.

Neuhauser , M., Weinstein, R., Rydman, R., Danziger,

L., Karam, G., & Qinn, J. (2003). Antibiotic resistance

among gram-negative bacilli in US intensive care units:

Implications for flouroquinolone use. JAMA, 289, 885-

Gaynes , R., Edwards, J., & National Nosocomial

Infections Surveillance System (2005). Overview of

Nosocomial Infections Caused by Gram-Negative Bacilli.

Clinical Infectious Diseases, 41, 848–54.

Lister P., Wolter D., Hanson N., (2009). Antibacterialresistant

Pseudomonas aeruginosa: Clinical impact

and complex regulation of chromosomally encoded

resistance mechanisms. Clinical Microbiology Reviews,

(4).

Obritsch , M., Fish, D., Maclare, R., & Jung, R. (2004).

National surveillance of antimicrobial resistance in

Pseudomonas aeruginosa isolates obtained from

intensive care unit patients from 1993 to 2002.

Antimicrobial Agents and Chemotherapy 48, 4606-

Livermore D., (2002). Multiple mechanisms of

antimicrobial resistance in Pseudomonas aeruginosa:

Our worst nightmare? Clinical Infectious Disease. 34,

-40

Vonberg , P., Wolter, A., Chaberny, I., Kola, A., Ziesing,

S., Suerbaum, S., et al. (2008). Epidemiology of

multi-drug-resistant Gram-negative bacteria:Data

from an university hospital over a 36-month period.

International Journal of Hygiene Environmental-Health,

(3-4), 251–257.

Noue´r S., Nucci M., de-Oliveira M., Pellegrino

F., Moreira B., (2005) Risk factors for acquisition

of multidrug-resistant Pseudomonas aeruginosa

producing SPM metallo- lactamase. Antimicrobial

Agents and Chemotherapy. 49(9) 3663–3667.

Pop-Vicas A., Strom J., Stanley K., D’Agata E., (2008).

Multidrug-resistant gram-negative bacteria among

patients who require chronic hemodialysis. Clinical

Journal of American Society of Nephrology, 3(3), 752-

Cosgrove S., (2006) The relationship between

antibicrobial resistance and patient outcomes:

Mortality, length of hospital stay and healthcare costs.

Clinical Infectious Diseases. 42(Suppl 2) S82-9.

Shorr, A., (2009) Review of studies of the impact on

gram-negative bacterial resistance on outcomes in

the intensive care unit. Critical Care Medicine, 37 (4),

-1469.

Turton J.F, M.E. Kaufmann, J. Glover, J.M. Coelho, M.

Warner, R.”Pike and T.L. Pitt. 2005. Detection and

typing of integrons in epidemic strains of Acinetobacter

baumannii found in the United Kingdom. J. Clin.

Microbiol. 43: 3074–3082.

Nemec A., L. Dolzani, S. Brisse, P. van den Broek and

L. Dijk- shoorn. 2004. Diversity of aminoglycosideresistance

genes and their association with class 1

integrons among strains of pan-European Acinetobacter

baumannii clones. J. Med. Microbiol. 53:1233–1240.

Zarrilli R., M. Crispino, M. Bagattini, E. Barretta, A.

Di Popolo, M. Triassi and P. Villari. 2004. Molecular

epidemiology of sequential outbreaks of Acinetobacter

baumannii in an intensive care unit shows the

emergence of carbapenem resistance. J. Clin. Microbiol.

: 946–953.

Ruiz-Martínez L, López-Jiménez L, Fusté E, Vinuesa

T, Martínez JP, Viñas M. 2011.Class 1 integrons in

environmental and clinical isolates of Pseudomonas

aeruginosa. Int J Antimicrob Agents 38:398–402.

Elbourne LD, Hall M: Gene cassette encoding a 3-N

–aminoglycoside acetyltransferase in a chromosomal

integron .2006. Antimicrob Agents Chemother,

:2270–2271.

Jeong JH, Shin KS, Lee JW, Park EJ, Son SY: Analysis

of a novel class 1integron containing metallo-betalactamase

gene VIM-2 in Pseudomonas aeruginosa J

Microbiol 47:753–759.

Fluit AC, Schmitz FJ: 2004. Resistance integrons and

super-integrons. Clin Microbiol Infect 10:272–288.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Journal of Communicable Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.